Osteoporosis International最新文献

According to the multivariable adjusted models, there was an inverse association between B-Cd levels and BMD, which was particularly evident in the subgroup analyses of other Hispanic and female individuals in the adolescent population. Clinicians and policy-makers should thoroughly consider the genetic implications of B-Cd levels in relation to BMD during the prevention and treatment of osteoporosis.

Objective: To investigate the associations between blood cadmium (B-Cd) levels and bone mineral density (BMD) in adolescents.

Methods: On the basis of the National Health and Nutrition Examination Survey (NHANES) database spanning from 2011 to 2018, we used weighted multiple regression, a generalized weighted model and smoothed curve methods to investigate the associations between B-Cd levels and BMD in adolescents. Subgroup analyses were also conducted to examine potential differences across age, sex, race, tobacco exposure status and other relevant variables.

Results: Among the 2427 participants, 52% were males, and 48% were females. In this study, multistage sampling data from the NHANES database were analysed, and the positive association between B-Cd levels and BMD shifted to a negative association after adjustment for age, sex and race. Subgroup analyses revealed a more pronounced association among females (β =  - 0.07, 95% CI: - 0.09, - 0.04, P < 0.001), other Hispanic individuals (β =  - 0.08, 95% CI: - 0.14, - 0.02, P = 0.012) and individuals exposed to tobacco (β =  - 0.04, 95% CI: - 0.06, - 0.01, P = 0.016).

Conclusion: The findings revealed a negative association between B-Cd levels and BMD in multivariable adjusted models.

Rheumatoid arthritis (RA) is a potentially devastating disorder associated with increased risk of fractures, but current studies do not completely evaluate the RA fracture risk profile. This study estimates fracture incidence by site of fracture and makes comparisons between RA and controls using the key variables gender, age, and comorbidities.

Background: Rheumatoid arthritis RA is a potentially devastating osteoimmunological disorder, predisposing to osteoporosis (OP), fragility fracture (FF), and major osteoporotic fractures (MOF). As few studies incorporate statistical matching, comorbidity and non-MOF sites, we compared the incidence of first FF, MOF, and non-MOF in RA patients with a matched control cohort adjusting for comorbidities.

Methods: This longitudinal cohort study uses routinely collected administrative data from the West Australian Rheumatic Disease Epidemiological Registry (WARDER) between 1980 and 2015. RA patients, as defined using International Classification of Disease (ICD) codes, were compared to hospitalised patients free of rheumatic disease. Case-control matching adjusted for age, gender, and comorbidities (Charlson Comorbidity Index). Incidence rates (IR) per 1000 person years (PY) with 95% confidence intervals (CI) were compared by incidence rate ratios (IRR).

Findings: In RA patients from 2000 to 2010, the first fracture IR was 18.3 (15.7-21.2) for an IRR of 1.32 (1.10-1.60). Upper limb, lower limb, and axial IR were 5.56 (95% CI 4.18-7.26), 10.60 (95% CI 8.66-12.87), and 2.47 (95% CI 2.58-3.68) with IRR of 1.18 (95% CI 0.84-1.65), 1.44 (95% CI 1.19-1.86), and 1.01 (95% CI 0.61-1.63) respectively. The first fracture IR increased 6 years before first RA hospital record (RR 1.58, CI 1.05-2.39).

Conclusions: After age, gender, and comorbidity adjustment, RA is associated with a 32% higher incidence of first fracture, increased MOF, and a fracture incidence that is already increased before a first recorded RA diagnosis. This suggests a need for early attention to prevention of all fractures in RA patients.

The prevalence of AAC in patients attending a Fracture Liaison Service is 27.6%. Prevalent vertebral fractures were associated with AAC, but not with severe AAC in patients without CVD. Fracture location and BMD were not related to AAC or severe AAC.

Purpose: Abdominal aortic calcification (AAC) is associated with an increased risk of cardiovascular disease (CVD), osteoporosis and fractures. We aimed to analyze the prevalence and severity of AAC and to assess whether index fracture location, bone mineral density (BMD) and prevalent VFs are associated with AAC in patients with a recent fracture.

Methods: Cross-sectional cohort study of patients with a recent clinical fracture (aged 50-90 years) attending the FLS. Patients received a BMD measurement and lateral spine imaging using Dual-energy X-ray absorptiometry. AAC prevalence was assessed using the AAC-24 score and categorized as none, moderate (AAC-24 1-4) and severe (AAC-24 ≥ 5). Multivariate logistic regression analyses were performed to study the association between risk factors and AAC presence/ severity.

Results: AAC was present in 478 (27.6%) of 1731 patients of whom 207 (43.3%) had moderate and 271 (56.7%) severe AAC. The presence of AAC was associated with age, BMI, smoking, history of CVD and prevalent grade 2 or 3 VFs, but index fracture location and BMD were not associated with AAC or severe AAC. In patients with AAC (n =  318) without a history of CVD, there was no association between index fracture location and BMD. In that subgroup, severe AAC was not associated with prevalent VFs.

Conclusions: In FLS patients, the prevalence of AAC and severe AAC was 27.6% and 15.7%. Index fracture location and BMD were not associated with AAC or severe AAC. Prevalent VFs were associated with AAC, but not with severe AAC in the subgroup of patients without CVD.

The current study aimed to systematically review the literature on the accuracy of artificial intelligence (AI) models for osteoporosis (OP) diagnosis using dental images. A thorough literature search was executed in October 2022 and updated in November 2023 across multiple databases, including PubMed, Scopus, Web of Science, and Google Scholar. The research targeted studies using AI models for OP diagnosis from dental radiographs. The main outcomes were the sensitivity and specificity of AI models regarding OP diagnosis. The "meta" package from the R Foundation was selected for statistical analysis. A random-effects model, along with 95% confidence intervals, was utilized to estimate pooled values. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was employed for risk of bias and applicability assessment. Among 640 records, 22 studies were included in the qualitative analysis and 12 in the meta-analysis. The overall sensitivity for AI-assisted OP diagnosis was 0.85 (95% CI, 0.70-0.93), while the pooled specificity equaled 0.95 (95% CI, 0.91-0.97). Conventional algorithms led to a pooled sensitivity of 0.82 (95% CI, 0.57-0.94) and a pooled specificity of 0.96 (95% CI, 0.93-0.97). Deep convolutional neural networks exhibited a pooled sensitivity of 0.87 (95% CI, 0.68-0.95) and a pooled specificity of 0.92 (95% CI, 0.83-0.96). This systematic review corroborates the accuracy of AI in OP diagnosis using dental images. Future research should expand sample sizes in test and training datasets and standardize imaging techniques to establish the reliability of AI-assisted methods in OP diagnosis through dental images.

Falls pose a significant threat to human health and safety. Accurately assessing the protective effectiveness of fall protection products can significantly reduce the occurrence of fall accidents. This paper systematically reviews the types and risk factors of human falls and then discusses the current research status and future prospects of various test methods for human fall protection. A literature search was conducted in databases such as Web of Science, Google Scholar, and Scopus. This study focuses on experimental methods for human fall testing, simulation model experiments, and finite element simulations, providing an outlook on future development trends. In the discussion of three different fall testing methods, research indicates that human fall simulation testing faces limitations such as ethical concerns and safety issues. Although simulation experiments allow for multiple tests in a short period, the complexity and accuracy of the models may affect the reliability of the results. By integrating more experimental data, optimizing the design of human models, and incorporating finite element simulation technology, the scope of testing applications can be expanded, thereby improving the effectiveness of protective product designs. In conclusion, future research on fall protection testing methods should aim to establish unified international standards, which will enhance consistency and repeatability in testing, facilitating better comparison and evaluation of the effectiveness of various protective measures. Furthermore, the integration of more experimental data with real-world scenarios, the optimization of human models and test environments, and the promotion of finite element simulation technology will be crucial in enhancing the precision of protective assessments.

Low bone mineral density is highly prevalent in sickle cell disease (SCD); whether bisphosphonates can safely preserve or increase bone mass in SCD adults remains unknown. In this study, lumbar spine bone density remained stable with alendronate use, and treatment-related side effects were mostly mild and self-limited.

Purpose: To describe the effects of alendronate in adults with sickle cell disease (SCD) and osteoporosis.

Methods: We reviewed retrospective clinical data from adults with SCD and osteoporosis treated with alendronate at a single center in Brazil (2009-2019). Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DXA) of the lumbar spine, femoral neck, and total hip. We analyzed BMD changes by alendronate treatment duration (months), stratified by sex, skeletal site, and SCD genotype.

Results: Sixty-four SCD adults with osteoporosis (69% females, 73% HbSS, mean age ± standard deviation 42.4 ± 10.9 years) received alendronate for a median (interquartile range) of 48 (29, 73) months. Compared with males, females had significantly lower baseline BMD (g/cm²) at the femoral neck (0.72 vs 0.85, p =  < 0.001) and total hip (0.79 vs 0.88, p = 0.009). The between-sex differences in BMD changes were insignificant. Mean lumbar spine BMD significantly changed by 0.0357 g/cm² (p = 0.028) in those on alendronate for > 5 years. Four adults (6.3%) reported mild therapy-related side effects. An atypical femoral diaphysis fracture, attributed to alendronate, was incidentally noted in a 37-year-old man on treatment for 4 years.

Conclusion: In this retrospective cohort of adults with SCD and osteoporosis on alendronate for a median of 48 months, we found no significant interactions between sex and changes in lumbar spine, femoral neck, or total hip BMD with alendronate. Lumbar spine BMD was stable in those on alendronate for < 5 years. Side effects of alendronate were mild, though one patient developed an atypical femoral fracture.

Increased fracture risk due to oral glucocorticoids (GCs) rapidly decreases with GC discontinuation. However, evidence for this is limited. We found that fracture risk decreased rapidly in the first year after GC discontinuation, while hip fracture risk remained higher than reference levels for about two years after GC discontinuation.

Purpose: We investigated changes in fracture risk following discontinuation of long-term oral glucocorticoids (GCs) using Japan's nationwide health insurance claims database (NDBJ).

Methods: We identified patients aged ≥ 50 years who initiated GC therapy in 2012-2019. Those receiving ≥ 5 mg (prednisolone or equivalent, PSL)/day for ≥ 72 days in the initial 90 days of GC therapy were classified as the GC-exposure group, and those receiving < 5 mg PSL/day for < 30 days were classified as the reference group. Patients discontinuing GC after 90 days of GC therapy were classified as the GC-discontinuation group; all others were classified as the GC-continuation group. We tracked the incidence rates of hip and clinical vertebral fractures for up to 990 days, and assessed fracture risk after GC discontinuation by hazard ratios (HR) adjusted by inverse probability weighting using propensity scores for GC discontinuation.

Results: There was a total of 52,179 GC-discontinuation, 91,969 GC-continuation, and 43,138 reference group women, and 57,560, 93,736, and 33,696 men in the corresponding groups, respectively. According to adjusted HRs, incidence rates of fractures were significantly lower in the GC-discontinuation group than in the GC-continuation group in the initial 90 days after GC discontinuation and remained significant for 360 days, except for hip fracture in men. HRs for hip fractures remained significantly higher in the GC-discontinuation group compared to the reference group for 720 days post-discontinuation.

Conclusion: Fracture risk declines rapidly in the first year after GC discontinuation, but vigilance is necessary as the increased risk persists for two years post-discontinuation.

This study demonstrates how complex bone microarchitectural features can be summarized to describe bone adaptations seen with aging in women, which are consistent with the stages of osteoporosis. Additionally, we showed familial resemblance in these bone microarchitectural traits between mothers and daughters that can be used to predict bone adaptations.

Introduction: Patient-specific characterization of bone quality can reduce complex microarchitectural features to common combinations of bone characteristics, known as bone phenotypes. This study investigated whether there is a general trend in bone phenotype change over time seen with aging in females and whether there is a familial resemblance to phenotype membership between mothers and daughters.

Methods: Bone phenotype membership was calculated on biological mother and daughter pairs (Participants = 101), scanned using high resolution peripheral quantitative computed tomography, to the three pre-defined phenotypes (healthy, low volume, and low density). The trajectory of bone phenotype with age was explored using all participant's data. Linear regression models were used to assess the familial resemblance of phenotyping in the mother-daughter pairs.

Results: When stratified for age, the trajectory of the phenotype membership transitioned from healthy (20-40 years), to low volume (40-60 years), to low density (60-80 years), which similarly aligns with the stages of osteoporosis observed in females. Familial resemblance (½h²) was observed in the healthy phenotype (β = 0.432, p < 0.01). Predictive modelling showed a significant association in phenotype membership between mothers and daughters in the healthy (R² = 0.347, p = 0.04) and low volume (R² = 0.416, p < 0.01) phenotypes, adjusted for age, height, and weight.

Conclusion: Our results suggest that phenotype membership in females changes with age in a pattern that is consistent with the stages of osteoporosis. Additionally, we showed familial resemblance in bone phenotype, which can be used to predict bone adaptations between mothers and daughters that are associated with bone loss with aging.

This study aims to understand how osteoporosis medication acceptance varies across countries with differing guidance on treatment threshold and influence of clinical and demographic factors. A total of 79.2% accepted treatment at a fracture probability at or below the treatment threshold. Fracture history and age did not strongly impact acceptance, suggesting a need for improved fracture risk communication.

Purpose: This part of the Improving Risk Communication in Osteoporosis (RICO) study aims to understand patients' willingness to initiate osteoporosis treatment given a hypothetical fracture probability-derived from the FRAX® Risk Assessment Tool-and how age, fracture history, and numeric literacy may influence this.

Methods: In 2022-2023, 332 postmenopausal women at risk of fracture were interviewed from nine countries to determine participants' Fracture Risk Decision Point (FRDP), the lowest probability of major osteoporotic fracture at which they would accept an osteoporosis medication. Participants' FRDP was evaluated given eight hypothetical 10-year FRAX scores.

Results: In countries with FRAX-based treatment thresholds, over half of the participants per country reported an FRDP that was below the threshold. Collectively, 79.2% demonstrated FRDPs at or below their respective threshold. Age and fracture history did not have a strong influence on FRDP; however, those who demonstrated higher levels of numeric literacy reported a significantly higher median FRDP (10%) compared to those who showed lower levels (5%, p < 0.001).

Conclusions: Most patients were willing to accept an osteoporosis medication prescription at a hypothetical FRAX probability that was even lower than that of their nationally recommended treatment threshold. Literacy scores had a significant influence on FRDP whereas age and fracture history did not.